NEW YORK (GenomeWeb News) – Proteomics firm ProteoMedix said today that it has closed on a Series B equity funding round, raising CHF 3.2 million ($3.62 million) from existing and new investors.

The Zurich-based company, which spun out of the lab of Swiss Federal Institute of Technology researcher Ruedi Aebersold in 2010, plans to use the funds to continue development of its lead product, a protein test for aiding detection of prostate cancer.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.